Last updated 2026-07-26
- Raised $46.5M Series D led by aMoon Fund, May 2021
- Raised $22M H Round Extension led by Flerie Invest AB, Dec 2025
- Raised $12.5M Series E led by Myeloma Investment Fund, Oct 2022
Total raised
$122.8M
Last: Undisclosed Round 2025-09
Stage
Series F
Founded
2005
Headcount
25
HQ
Modi'in-Maccabim-Re'ut, Israel
Sector
Health Tech & Life Sciences
About
KAHR Medical is a clinical-stage biotechnology company developing novel immune-recruiting therapies that treat cancer by unleashing the synergistic power of the body's innate and adaptive immune responses. The company's proprietary Multifunctional Immuno-Recruitment Protein (MIRP) technology utilizes engineered fusion proteins that bind overexpressed tumor antigens and activate immune effector pathways. Their lead product, DSP107, is a first-in-class bi-specific CD47x4-1BB targeting T-cell engager for the treatment of various cancers, including colorectal cancer and multiple myeloma. KAHR Bio was founded based on technology developed at the University of Pennsylvania and Thomas Jefferson University.
Funding history · 11 rounds · $122.8M total
2025-12
H Round Extension
$22.0M
★ Flerie Invest ABaMoon FundCancer Focus FundPeregrine VenturesConsensus Business Group (CBG)
2025-08
H Round
Undisclosed
★ Peregrine Ventures
2025-04
G Round
Undisclosed
★ Peregrine Ventures
2024-01
F Round
$770K
★ Peregrine Ventures
2022-10
E Round
$12.5M
★ Myeloma Investment Fund
2021-05
D Round
$46.5M
★ aMoon FundBVF PartnersDafna CapitalOriella LimitedPavilion CapitalFlerie Invest ABCancer Focus FundPeregrine VenturesShavit Capital FundHadasit Bio-HoldingsMirae Asset Venture Investment
2020-01
C Round
$18.0M
★ Flerie Invest ABOriella LimitedPavilion CapitalHadasit Bio-HoldingsMirae Asset Venture Investment
2015-11
B Round
$12.0M
★ DSC Investment★ Flerie Invest AB★ Korea Investment Partners★ Mirae Asset Venture Investment
2013-08
A Round
$7.5M
★ Sanofi Ventures★ Flerie Invest AB★ Hadasit Bio-Holdings
2011-11
Seed Extension
$3.0M
★ Sanofi★ Hadasit Bio-Holdings
2008-12
Seed
$500K
★ Hadasit Bio-Holdings★ Office of the Chief Scientist
Headcount over time
From 11 (2018-12) to 23 (2026-01) · +12 (+109%) · 14 points · source: Finder history + radar grounding
Q&A
- What is KAHR Medical's primary focus?
- KAHR Medical is a biopharmaceutical company that develops novel drug platforms based on bi-functional, immunotherapeutic fusion proteins for cancer treatment.
- When was KAHR Medical founded?
- KAHR Medical was founded in September 2005.
- What is KAHR Medical's lead product?
- KAHR Medical's lead product is DSP107, a first-in-class bi-specific CD47x4-1BB targeting T-cell engager for the treatment of various cancers, including colorectal cancer and multiple myeloma.
- How many employees does KAHR Medical have?
- KAHR Medical has 25 employees, falling within the 11-50 employee bucket.
- What was KAHR Medical's most recent funding round?
- Key investors included Flerie AB and Peregrine Ventures.
- Which investors participated in KAHR Medical's D Round in November 2022?
- The D Round in November 2022 included investments from aMoon and BVF Partners.
- Did KAHR Medical receive FDA clearance for clinical trials?
- Yes, in August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.
- What was a significant financing event for KAHR Medical in 2021?
- In June 2021, KAHR Medical announced $46.5 million in financing to advance its multifunctional immunotherapeutic pipeline.
- What was the outcome of the Phase 2 study of DSP107 in colorectal cancer?
- In January 2026, KAHR Bio announced strong topline Phase 2 results for DSP107 in combination with anti-PD-L1 therapy in colorectal cancer.
Team · 1
Michal Dranitzki-Elhalel
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
cancerbiological-therapydrug-deliverydrug-discoverypharmaceuticalsautoimmune-diseaseschronic-patientsbiopharmaceuticalpharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | kahrbio.base44.app |
|---|---|
| linkedin.com/company/6724763 | |
| YouTube | youtube.com/channel/UCAHE_coSjQ1j76fTPMuJ0Yg |
Identifiers & details
| Legal name | KAHR Medical Ltd. |
|---|---|
| Founded | 2005-9 |
| Employees (exact) | 25 |
Radar intelligence
Patents
| EPO | 17 |
|---|
Web history (Wayback)
| Domain | kahrbio.base44.app |
|---|
Certificate / subdomain footprint
| Subdomains | 0 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513736249 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2005-09-25 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 1 |
| Registry events | 1 — charge (1) |
| Registered address | שדרות דם המכבים 28 מודיעין-מכבים-רעות |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-28 | רישום שעבוד |